Henning R. Stennicke
Chief Tech/Sci/R&D Officer bij FREELINE THERAPEUTICS HOLDINGS PLC
Profiel
Henning R.
Stennicke is currently the Chief Scientific Officer at Freeline Therapeutics Holdings Plc since 2022.
Prior to this, he worked as the Project Vice President-Global Development Biopharm at Novo Nordisk A.
He holds an MBA from the Technical University of Denmark and a graduate degree from the University of Copenhagen.
Actieve functies van Henning R. Stennicke
| Bedrijven | Functie | Begin |
|---|---|---|
| FREELINE THERAPEUTICS HOLDINGS PLC | Chief Tech/Sci/R&D Officer | 01-03-2022 |
Eerdere bekende functies van Henning R. Stennicke
| Bedrijven | Functie | Einde |
|---|---|---|
| NOVO NORDISK A/S | Corporate Officer/Principal | - |
Opleiding van Henning R. Stennicke
| Technical University of Denmark | Masters Business Admin |
| University of Copenhagen | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| NOVO NORDISK A/S | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Freeline Therapeutics Holdings Plc
 Freeline Therapeutics Holdings Plc BiotechnologyHealth Technology Freeline Therapeutics Holdings Plc engages in the business of developing and commercializing gene therapies. It also develops gene therapies for bleeding and other debilitating disorders. The company was founded by Markus Hörer and Amit Chunilal Nathwani in 2015 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
